PubRank

Gideon Bollag

Author PubWeight™ 134.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 21.36
2 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008 17.41
3 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010 17.31
4 Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007 10.27
5 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
6 The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010 6.54
7 RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010 4.70
8 Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006 4.48
9 A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 2005 2.51
10 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013 2.51
11 Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2011 2.22
12 CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013 2.19
13 Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008 2.06
14 PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010 2.02
15 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011 1.97
16 Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2012 1.92
17 Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004 1.84
18 Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011 1.84
19 Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med 2015 1.75
20 GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002 1.74
21 Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2011 1.73
22 A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 2004 1.64
23 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2009 1.59
24 Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res 2013 1.56
25 Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev 2007 1.48
26 Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 2010 1.48
27 The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2004 1.43
28 Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 2007 1.41
29 Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010 1.36
30 Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A 2014 1.15
31 Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A 2008 1.03
32 Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 2012 1.03
33 Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 2006 1.01
34 Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 2005 0.92
35 Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A 2013 0.91
36 Interrogating the kinome. Nat Biotechnol 2011 0.86
37 The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrol Dial Transplant 2011 0.83
38 Sending out an SOS. Nat Genet 2007 0.82
39 PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 2013 0.82
40 Scaffold-based design of kinase inhibitors for cancer therapy. Curr Opin Genet Dev 2009 0.80
41 An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell 2016 0.79
42 Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. Endocr Rev 2009 0.75